

AMENDMENTS TO THE CLAIMS

Please amend claims 24, 32, 34, 36, 44, and 46. Please add new claims 54-57.

Please cancel claims 25, 28, 31, 33, 37, 40, 43, 45, and 48-53 without prejudice or disclaimer. This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-23 (Cancelled)

24. (Currently amended) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation comprising:

~~at least 45 mgml⁻¹ of fulvestrant;~~

~~a mixture of from 17 — 23% w/v of ethanol and benzyl alcohol;~~

~~12 — 18% w/v of benzyl benzoate; and~~

about 50 mgml⁻¹ of fulvestrant;

about 10% w/v of ethanol;

about 10% w/v of benzyl alcohol;

about 15% w/v of benzyl benzoate; and

a sufficient amount of castor oil vehicle;

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least ~~two~~ four weeks.

25. (Cancelled)

26. (Previously presented) The method of claim 24, wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml^{-1} .
27. (Previously presented) The method of claim 24, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
28. (Cancelled)
29. (Previously presented) The method of claim 24, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.
30. (Previously presented) The method of claim 24, wherein the method further comprises once monthly administration of the formulation.
31. (Cancelled)
32. (Currently amended) The method of ~~claim 31~~ claim 26, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
33. (Cancelled)
34. (Currently amended) The method of ~~claim 33~~ claim 32, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.

35. (Previously presented) The method of claim 34, wherein the method further comprises once monthly administration of the formulation.
36. (Currently amended) A method for treating a hormonal dependent benign or malignant disease of the breast or reproductive tract comprising administering intramuscularly to a human in need of such treatment a formulation consisting essentially of:

~~at least 45 mgml⁻¹ of fulvestrant;~~

~~a mixture of from 17—23% w/v of ethanol and benzyl alcohol;~~

~~12—18% w/v of benzyl benzoate; and~~

~~a sufficient amount of castor oil vehicle;~~

about 50 mgml⁻¹ of fulvestrant;

about 10% w/v of ethanol;

about 10% w/v of benzyl alcohol;

about 15% w/v of benzyl benzoate; and

wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml⁻¹ for at least ~~two~~four weeks.

37. (Cancelled)
38. (Previously presented) The method of claim 36, wherein the therapeutically significant blood plasma fulvestrant concentration is at least 8.5 ngml⁻¹.

39. (Previously presented) The method of claim 36, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
40. (Cancelled)
41. (Previously presented) The method of claim 36, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.
42. (Previously presented) The method of claim 36, wherein the method further comprises once monthly administration of the formulation.
43. (Cancelled)
44. (Currently amended) The method of ~~claim 43~~ claim 38, wherein the hormonal dependent benign or malignant disease of the breast or reproductive tract is breast cancer.
45. (Cancelled)
46. (Currently amended) The method of ~~claim 45~~ claim 44, wherein the method comprises administering intramuscularly to a human in need of such treatment 5 mL of the formulation.
47. (Previously presented) The method of claim 46, wherein the method further comprises once monthly administration of the formulation.

Claims 48-53 (Cancelled)

54. (New) The method according to claim 24, wherein the formulation is administered in a divided dose.
55. (New) The method according to claim 35, wherein the formulation is administered in a divided dose.
56. (New) The method according to claim 36, wherein the formulation is administered in a divided dose.
57. (New) The method according to claim 47, wherein the formulation is administered in a divided dose.